Brief: LumiraDx Achieves CE Mark For Covid-19 Antigen Test On Amira, Its New Low-Cost Testing System
09/06/2022 14:50
June 9 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX ACHIEVES CE MARK FOR COVID-19 ANTIGEN TEST ON
AMIRA,
ITS NEW LOW-COST TESTING SYSTEM
Source text for Eikon: ID:nPn9W66mYa
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing